SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: GlobeNewswire
Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second RemissionHagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas - MD Anderson Cancer Center to serve as Committee Chair NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced the formation of the Steering Committee for its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line anti-leukemic therapy (CR2). “We continue to make important progress toward ensuring that our Phase 3 AML trial is a well-executed pivotal study and are working diligently toward its ti
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal [Seeking Alpha]Seeking Alpha
- A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into EuropeGlobeNewswire
- SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]Yahoo! Finance
SLS
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- SLS's page on the SEC website